Retinal and Choroidal Changes of Vitreoretinal Lymphoma from Active to Remission Phase after Intravitreal Rituximab

Maria Vittoria Cicinelli, Alessandro Marchese, Elisabetta Miserocchi, Chiara Giuffré, Luigi Berchicci, Giuseppe Querques, Francesco Bandello, Giulio Maria Modorati

Research output: Contribution to journalArticlepeer-review


Purpose: To identify main qualitative and quantitative changes by spectral-domain optical coherence tomography (SD-OCT) in eyes with vitreoretinal lymphoma (VRL) shifting form active to remission phase, after intravitreal rituximab (IVR). Methods: SD-OCT scans retrospectively assessed for: hyperreflective retinal dots (HRD), intraretinal infiltration, subretinal infiltration, outer retina (OR) fuzzy borders, and pigment epithelium detachments (PED).Central macular thickness (CMT) and choroidal thickness (CT) were measured. These features were examined in active and in remission phase. Results: Eighteen eyes of nine patients enrolled. Patients received 5.3 ± 2.1 IVR according to a 2-weekly or monthly schedule. In remission phase, presence of HRD (p = 0.02), intraretinal infiltration (p = 0.02), OR fuzzy borders (p = 0.01) significantly reduced. Treatment frequency did not influence rate of disappearance of these features. CMT (p = 0.04) and CT (P = 0.004) became thinner. Conclusions: Signs referable to lymphoma-induced inflammation (CMT, CT, HRD) and infiltration (intraretinal infiltrates, OR fuzzy borders) decreased in remission phase. Further comparative studies needed to identify the specific role of IVR in inducing these changes.

Original languageEnglish
Pages (from-to)637-646
Number of pages10
JournalOcular Immunology and Inflammation
Issue number4
Publication statusPublished - May 18 2020


  • Fundus autofluorescence
  • optical coherence tomography
  • primary vitreoretinal lymphoma
  • widefield imaging

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Retinal and Choroidal Changes of Vitreoretinal Lymphoma from Active to Remission Phase after Intravitreal Rituximab'. Together they form a unique fingerprint.

Cite this